PRS3 HEALTHCARE RESOURCE UTILIZATION AND CHARACTERIZATION OF PATIENTS WITH MODERATE TO SEVERE COPD AND A HISTORY OF EXACERBATIONS: SUB-ANALYSIS OF ARGENTINIAN PATIENTS ENROLLED IN THE IMPACT STUDY

Abstract

Limited information is available from low- and middle-income countries describing moderate/severe COPD-related healthcare resource utilization (HRU). We describe HRU for Argentinian subjects enrolled in IMPACT. IMPACT (NCT02164513), a 52-week, phase III, global study (N=10,355), evaluated fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus FF/VI or UMEC/VI in patients with moderate/severe COPD and history of exacerbations. We described demographic, clinical characteristics and HRU at baseline and during follow-up for Argentinian subjects. Average HRU per subject and estimated HRU annual rates are described for outpatient, inpatient and emergency room visits. 972 subjects enrolled from Argentina had similar demographic and clinical characteristics to the intention-to-treat (ITT) population, but higher use of combinations with inhaled corticosteroids (ICS) (90% vs. 77%) at baseline, mostly ICS + long-acting □2-agonist (67% vs. 32%) (a post-hoc summary). Lower proportion of Argentinian subjects had severe exacerbations within the previous year to screening and a higher proportion of moderate exacerbations versus ITT (8% vs. 26% for ≥1; 1% vs. 4% for ≥2); 63% of subjects had ≥2 moderate exacerbations versus 47% of the ITT population. Consistently, lower rates of on-treatment moderate/severe exacerbations were observed in Argentina, FF/UMEC/VI (0.65) versus FF/VI (0.74) or UMEC/VI (0.76), compared with the ITT population [(FF/UMEC/VI (0.92) versus FF/VI (1.05) or UMEC/VI (1.15)]. Generally, lower rates of COPD-related HRU were observed in the Argentinian population versus ITT, except for days spent in the intensive care unit [FF/UMEC/VI (0.21) versus FF/VI (0.18) or UMEC/VI (0.28) vs. ITT: FF/UMEC/VI (0.14) versus FF/VI (0.12) or UMEC/VI (0.19). Consistently, FF/UMEC/VI had fewer emergency room visits, and lower or similar outpatient visits compared to dual combinations in both groups. On-treatment exposure-adjusted exacerbation rates were lower with FF/UMEC/VI compared with dual therapy in both Argentinian and ITT populations. Similarly, COPD-related HRU was lower with FF/UMEC/VI compared with dual therapy for both populations.